Sensei Biotherapeutics doses first patient in breast cancer trial

May 5, 2026 7:30 AM

Sensei Biotherapeutics Inc. (NASDAQ: SNSE) announced it has dosed the first patient in a Phase 1b/2 trial evaluating its investigational ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found